First-line Treatment For Untreated Multiple Myeloma, In Patients Aged 65 Years And Over, Or For Those Not Eligible For High-dose Chemotherapy Due To Significant Co-morbidity Such As Cardiac Risk Factors (in Combination With Melphalan And Prednisolone):
Adult 18-75 Years: 200 Mg Once Daily At Bedtime For a 6-week Cycle For A Maximum Of 12 Cycles
Adult 76 Years And Above: 100 Mg Once Daily At Bedtime for a 6-week Cycle For A Maximum Of 12 Cycles
Content
Cap 50mg /100mg: Thalidomide 50mg /100mg.
Pregnancy
Positive Evidence Of Risk: Avoid
Stability
Immunomodulator and Anti-inflammatory
Contra Indications
Patients With Pre-existing Peripheral
Neuropathy Should Not Be Treated With Thalidomide Unless The Potential Clinical Benefits Outweigh The Risk
Precautions
Patients With Pre-existing Peripheral
Neuropathy Should Not Be Treated With Thalidomide Unless The Potential Clinical Benefits Outweigh The Risk